Peripheral Liquid Embolic Agents Market is expected to reach US$ 81.41 Million by 2031

Precipitating Liquid Embolic Agents Segment to Hold Larger Share of Peripheral Liquid Embolic Agents Market During 2024–2031

According to our latest study on “Global Peripheral Liquid Embolic Agents Market Forecast to 2031 – Global Impact and Analysis – by Type, Application, and Geography,” the market is expected to grow from US$ 40.42 million in 2023 to US$ 81.41 million by 2031; it is estimated to register a CAGR of 9.1% from 2021 to 2031. The report emphasizes the key factors driving the market and prominent players' developments. Factors such as the rising incidence of peripheral vascular diseases and increasing demand for minimally invasive procedures propel the peripheral liquid embolic agents market growth.

Each embolic agent has unique properties that make it desirable for specific clinical conditions. However, no embolic agent is suitable for all indications. There is a growing use of liquid embolic agents in peripheral procedures. Liquid embolic agents do not rely on the patient's coagulation system for complete occlusion and can be effective in patients affected by severe coagulopathy. If a catheter cannot reach a bleeding site, liquid agents can provide embolization distal to the catheter tip. For peripheral use, an optimal liquid embolic agent or product must be easy to use as they have deep penetration applications that are reproducible and controllable. Also, the agents must be safe from off-target embolization and compatible with aqueous contrast agents, standard microcatheters, and drugs. Further, the market is progressing toward meeting the demands of a changing healthcare landscape, and the growing focus and developments in temperature-induced phase change systems and pH-triggered embolic agents are expected to bring new peripheral liquid embolic agents market trends in the coming years.

Peripheral Liquid Embolic Agents Market, by Geography, 2023 (%)

Source: The Insight Partners Analysis

Increasing Demand for Minimally Invasive Procedures Fuels Market Growth

The patients are increasingly preferring noninvasive procedures owing to the low postoperative pain and complications, shorter hospital stays, fast recovery, and others. Trans Arterial Chemo Embolization (TACE) is a minimally invasive procedure used to treat hepatocellular carcinoma. The TACE procedure is for patients suffering from asymptomatic and unresectable liver cancer. It can be used to shrink the size of the tumor, thereby making the patient entitled to liver transplantation. TACE is an evolution from a formerly applied technique called Trans-catheter Arterial Embolization (TAE). The procedure allows selectively embolizing the hepatic artery branches while leaving out the healthy hepatic tissues. Prostatic artery embolization (PAE) is also a minimally invasive therapy implemented as an elective outpatient technique to treat lower urinary tract symptoms (LUTS), that is secondary to benign prostatic hyperplasia (BPH).

In the last few decades, the preference has shifted from open surgery to minimally invasive procedures with real-time imaging. These techniques often involve passing catheters from a superficial, easily accessible blood vessel to a more distant, distal blood vessel to gain access to every organ in the body. Such minimally invasive, image-guided procedures have expanded the spectrum of treatable vascular diseases and often result in comparatively lower postoperative morbidity compared to open surgical techniques. Embolization is a commonly performed procedure in which a drug is administered through a catheter to obstruct blood flow within a target vessel. Embolization has established itself as a minimally invasive technique for achieving vascular occlusion. Liquid embolic agents have attracted considerable attention as they penetrate deep into the vessels and independently of thrombus formation, which relies on the patient's coagulation system. The drugs have been used to treat blood vessel abnormalities, including aneurysms, AVMs, tumors, and others. One of the specific properties of liquid embolic agents is their ability to fill the target vessel and induce vascular occlusion by advancing with blood flow and penetrating deeper into the vascular bed. Interest in liquid and gel embolic agents has increased because they are not dependent on the patient's clotting ability and can reach areas where catheters and coils are inadequate for more peripheral procedures. These agents are dissolved in an organic solvent and then injected into the target arteries. After injection, the agent transitions to a solid implant through polymerization, precipitation, or cross-linking.

The rise in awareness about minimally invasive procedures and the availability of reimbursement for the procedures foster the demand for a minimally invasive procedures, which bolsters the growth of the peripheral liquid embolic agents market.

Peripheral Liquid Embolic Agents Market, by Type:

Based on type, the peripheral liquid embolic agents market analysis is carried out by considering the following subsegments: polymerizing liquid embolic agents and precipitating liquid embolic agents. The precipitating liquid embolic agent segment held a larger market share in 2023 and is anticipated to register a higher CAGR of 9.3% during the forecast period. Precipitants are combined with a solvent. After dilution in the blood, the polymer precipitates, and the mechanism of action is similar to that of ethylene vinyl alcohol (EVOH). EVOH is a copolymer with a dimethyl sulfoxide (DMSO) solvent and a suspension of (radiopaque) micronized tantalum powder. When injected through a catheter and mixed with blood, the solvent is diluted, causing the copolymer to precipitate into a spongy plaster with a gel-like consistency, resulting in vascular occlusion at a slower rate than glue. Onyx has been used to embolize arteriovenous malformations (AVMs). Other applications include embolization of visceral aneurysms/pseudoaneurysms, endoleaks, portal vein embolization, and end-organ embolization, such as renal angiomyolipomas (AML). Poly(2-hydroxyethyl methacrylate) or pHEMA is a biocompatible, hydrophilic, optically transparent, and non-degradable polymer. pHEMA has been used in various biomedical applications over the years, owing to advances in research and development. These applications include soft contact lenses, ocular drug delivery and controlled drug delivery systems, bone tissue regeneration, artificial corneas, artificial skin, breast augmentation, catheters, wound dressings, intrauterine inserts, and prostheses. Onyx (Medtronic, Dublin, Ireland) is an example of a currently available precipitant. Squid (Emboflu, Gland, Switzerland), precipitating hydrophobic injectable liquid (PHIL; Terumo Medical), Easyx (Antia Therapeutics AG, Bern, Switzerland), Lava (Black Swan Vascular Inc, Hayward, CA), and others are available in various concentrations.

Peripheral Liquid Embolic Agents Market, by Application:

In terms of application, the market is segmented into endoleak type II, malformations, bleedings and trauma, varicose vein, tumors, and visceral aneurysm. The endoleak type II segment held the largest peripheral liquid embolic agents market share in 2023. However, the bleedings and trauma segment is anticipated to register the highest CAGR during 2023–2031.

Peripheral Liquid Embolic Agents Market, by Geography:

The geographic scope of the peripheral liquid embolic agents market report covers North America (Canada and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). The market in North America held the largest peripheral liquid embolic agents market share in 2023. The regional market was valued at 3.62 million in 2023 and is expected to register a CAGR of 8.7% during 2023–2031. The growth of the market in North America is attributed to the increasing cases of aneurysms, trauma, and others across the region. The market in Canada is anticipated to grow because of rising government support for addressing the increasing concerns regarding peripheral disorders. The market in Mexico is estimated to grow owing to the growing pharma industries and medical tourism across the country. Further, the increasing cases of varicose veins across the region drives the expansion of the peripheral liquid embolic agents market size. Canada held the largest share in 2023 in North America. According to the Canadian Hemophilia Society, about 300,000 Canadians carry a gene for an inherited bleeding disorder. One in 10 people (i.e., ~30,000 Canadians) have severe symptoms that require medical attention. Only 10,000 people affected by hereditary bleeding disorders are enrolled in Canada's network of comprehensive hereditary bleeding disorder clinics. According to the Gray Foot and Orthotic Clinic, varicose veins affect the lives of 3.7 million Canadians.

The peripheral liquid embolic agents market report emphasizes major developments by prominent players. Medtronic, B Braun SE, Guerbet SA, Sirtex Medical Ltd, Balt, MicroVention Inc, Johnson & Johnson, and GEM srl are among the prominent players operating in the market. Medtronic is leading the peripheral embolic agents market, followed by Gem Srl, MicroVention Inc, Johnson and Johnson, and Balt. Medtronic product Onyx is widely used, followed by Cyanoacrylate glues provided by Gem Srl, Johnson and Johnson, and other market players. Additionally, new products, such as PHIL provided by MicroVention Inc, are expected to gain traction in developed countries as the price range of PHIL is higher than EVOH, and it can lead to affordability issues in developing countries. Moreover, the development of phase transitioning embolic agents is expected to direct the market growth in the coming years.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com